UCB SA (UCB.BR) News
Track canonical SquawkNews coverage tagged to UCB.BR, UCB SA. This hub brings together deduplicated headlines about brussels, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 2 indexed stories across 2 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
UCB flags new three-year EADV 2026 data showing earlier Bimzelx use improves lesion resolution
UCB said three-year analyses from its EADV 2026 presentation of BIMZELX in moderate-to-severe hidradenitis suppurativa indicate earlier use improves full inflammatory lesion clearance versus later treatment, with stronge
EARNINGS | Sep 30, 2026, 05:06 AM UTC
H
Berenberg Updates Price Target, Estimates for UCB on Recent Pipeline Deals
() -- Berenberg revised its price target and earnings forecasts for UCB (UCB.BR) to account for the biopharmaceutical company's recent acquisitions. "UCB recently closed three pipeline transactions: Candid Therapeutics,
EARNINGS | Jul 03, 2026, 06:47 AM UTC